335 related articles for article (PubMed ID: 26874840)
1. Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED).
Rinaldi F; Galbiati A; Marelli S; Ferini Strambi L; Zucconi M
Curr Treat Options Neurol; 2016 Feb; 18(2):7. PubMed ID: 26874840
[TBL] [Abstract][Full Text] [Related]
2. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
Garcia-Borreguero D; Kohnen R; Silber MH; Winkelman JW; Earley CJ; Högl B; Manconi M; Montplaisir J; Inoue Y; Allen RP
Sleep Med; 2013 Jul; 14(7):675-84. PubMed ID: 23859128
[TBL] [Abstract][Full Text] [Related]
3. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome.
Silber MH; Becker PM; Earley C; Garcia-Borreguero D; Ondo WG;
Mayo Clin Proc; 2013 Sep; 88(9):977-86. PubMed ID: 24001490
[TBL] [Abstract][Full Text] [Related]
4. An update on the treatment of Restless Legs Syndrome/Willis-Ekbom Disease: prospects and challenges.
Zucconi M; Galbiati A; Rinaldi F; Casoni F; Ferini-Strambi L
Expert Rev Neurother; 2018 Sep; 18(9):705-713. PubMed ID: 30095315
[TBL] [Abstract][Full Text] [Related]
5. Emerging Concepts of the Pathophysiology and Adverse Outcomes of Restless Legs Syndrome.
Romero-Peralta S; Cano-Pumarega I; García-Borreguero D
Chest; 2020 Sep; 158(3):1218-1229. PubMed ID: 32247713
[TBL] [Abstract][Full Text] [Related]
6. Management of treatment failure in restless legs syndrome (Willis-Ekbom disease).
Garcia-Borreguero D; Cano-Pumarega I; Marulanda R
Sleep Med Rev; 2018 Oct; 41():50-60. PubMed ID: 29602660
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.
Garcia-Borreguero D; Silber MH; Winkelman JW; Högl B; Bainbridge J; Buchfuhrer M; Hadjigeorgiou G; Inoue Y; Manconi M; Oertel W; Ondo W; Winkelmann J; Allen RP
Sleep Med; 2016 May; 21():1-11. PubMed ID: 27448465
[TBL] [Abstract][Full Text] [Related]
8. Restless legs syndrome.
Klingelhoefer L; Bhattacharya K; Reichmann H
Clin Med (Lond); 2016 Aug; 16(4):379-82. PubMed ID: 27481386
[TBL] [Abstract][Full Text] [Related]
9. Advancing synthetic therapies for the treatment of restless legs syndrome.
de Biase S; Pellitteri G; Gigli GL; Valente M
Expert Opin Pharmacother; 2019 Nov; 20(16):1971-1980. PubMed ID: 31424287
[No Abstract] [Full Text] [Related]
10. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Ferini-Strambi L; Marelli S; Galbiati A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of restless leg syndrome (Willis-Ekbom disease) during long-term dopaminergic treatment.
Garcia-Borreguero D; Benitez A; Kohnen R; Allen R
Postgrad Med; 2015; 127(7):716-25. PubMed ID: 26077324
[TBL] [Abstract][Full Text] [Related]
12. Restless legs syndrome/Willis Ekbom disease: evaluation and treatment.
Allen RP
Int Rev Psychiatry; 2014 Apr; 26(2):248-62. PubMed ID: 24892899
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for restless legs syndrome.
Ferini-Strambi L; Marelli S
Expert Opin Pharmacother; 2014 Jun; 15(8):1127-38. PubMed ID: 24745717
[TBL] [Abstract][Full Text] [Related]
14. Willis-Ekbom Disease or Restless Legs Syndrome?
Carlos K; Prado LB; Carvalho LB; Prado GF
Sleep Med; 2015 Sep; 16(9):1156-9. PubMed ID: 26298794
[TBL] [Abstract][Full Text] [Related]
15. Defining the phenotype of restless legs syndrome/Willis-Ekbom disease (RLS/WED): a clinical and polysomnographic study.
Rinaldi F; Galbiati A; Marelli S; Cusmai M; Gasperi A; Oldani A; Zucconi M; Padovani A; Ferini Strambi L
J Neurol; 2016 Feb; 263(2):396-402. PubMed ID: 26725086
[TBL] [Abstract][Full Text] [Related]
16. Living with Restless Legs Syndrome/Willis-Ekbom Disease.
Tachibana N
Sleep Med Clin; 2015 Sep; 10(3):359-67, xv. PubMed ID: 26329446
[TBL] [Abstract][Full Text] [Related]
17. What patients do to counteract the symptoms of Willis-Ekbom disease (RLS/WED): Effect of gender and severity of illness.
Gupta R; Goel D; Ahmed S; Dhar M; Lahan V
Ann Indian Acad Neurol; 2014 Oct; 17(4):405-8. PubMed ID: 25506161
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and quality of life and sleep in children and adolescents with restless legs syndrome/Willis-Ekbom disease.
Sander HH; Eckeli AL; Costa Passos AD; Azevedo L; Fernandes do Prado LB; França Fernandes RM
Sleep Med; 2017 Feb; 30():204-209. PubMed ID: 28215250
[TBL] [Abstract][Full Text] [Related]
19. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
[TBL] [Abstract][Full Text] [Related]
20. Natural course of restless legs syndrome/Willis-Ekbom disease: long-term observation of a large clinical cohort.
Mitterling T; Heidbreder A; Stefani A; Fritz J; Ulmer H; Poewe W; Högl B
Sleep Med; 2015 Oct; 16(10):1252-8. PubMed ID: 26429754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
